Dafinchi
Royalty Pharma Q1 2026 Guidance Change: Key Drivers and Market Outlook
This discussion highlights the key factors influencing Royalty Pharma's guidance update for Q1 2026, focusing on strategic adjustments and market conditions.
Read post
Detailed company information
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Aug 05, 2026
Earnings Transcript for 2026 - Q1Released: May 06, 2026
Earnings Transcript for 2025 - Q4Released: Feb 11, 2026
Earnings Transcript for 2025 - Q3Released: Nov 05, 2025
Earnings Transcript for 2025 - Q2Released: Aug 06, 2025
Earnings Transcript for 2025 - Q1Released: May 08, 2025
Earnings Transcript for 2024 - Q4Released: Feb 11, 2025
Earnings Transcript for 2024 - Q3Released: Nov 06, 2024
Earnings Transcript for 2024 - Q2Released: Aug 08, 2024
Earnings Transcript for 2024 - Q1Released: May 09, 2024
Earnings Transcript for 2023 - Q4Released: Feb 15, 2024
Earnings Transcript for 2023 - Q3Released: Nov 08, 2023
Earnings Transcript for 2023 - Q2Released: Aug 08, 2023
Earnings Transcript for 2023 - Q1Released: May 09, 2023
Earnings Transcript for 2022 - Q4Released: Feb 15, 2023
Earnings Transcript for 2022 - Q3Released: Nov 08, 2022
Earnings Transcript for 2022 - Q2Released: Aug 04, 2022
Earnings Transcript for 2022 - Q1Released: May 05, 2022
Earnings Transcript for 2021 - Q4Released: Feb 15, 2022
Earnings Transcript for 2021 - Q3Released: Nov 10, 2021
Earnings Transcript for 2021 - Q2Released: Aug 11, 2021
Earnings Transcript for 2021 - Q1Released: May 11, 2021
Earnings Transcript for 2020 - Q4Released: Feb 17, 2021
Earnings Transcript for 2020 - Q3Released: Nov 11, 2020
This discussion highlights the key factors influencing Royalty Pharma's guidance update for Q1 2026, focusing on strategic adjustments and market conditions.
Read postRoyalty Pharma increased its 2026 guidance primarily due to stronger expected portfolio receipts, supported by diversified portfolio momentum and key product developments, despite potential headwinds from regulatory and contractual factors.
Read post